The first study by Chavez et al. [91] found an enhanced systemic tumor antigen cross-presentation, type I IFN release from tumor cells, transcription of genes related to T cell activation and a CD169+ subpopulation of macrophages and dendritic cells in the combined therapy group. This evidence concerns the gene SIGLEC1 and neoplasm.